C
Celator Pharmaceuticals
Operator of a pharmaceutical company intended to improve clinical outcomes
At a glance
- Founded
- 1999
- Headquarters
- Dublin, Ireland
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Celator Pharmaceuticals.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series B and later7 investors entered at this stage
- RPROTH Capital Partners
- VWVentures West
- VSValence Life Sciences
- DADomain Associates
- TVTL Ventures
- TPThomas McNerney & Partners
- BABC Cancer Agency
Source: Dealroom Talent Intelligence.
Alumni founders
Former Celator Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
UHUpward HealthEst. 2017
NENeurogastrxEst. 2012
Cyril De ColleUnited StatesGlobal footprint
Patents
13 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Celator Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Celator Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.